Categories
Change Password!
Reset Password!
Combining Mesalamine with live combined Bifidobacterium, Lactobacillus, and Enterococcus capsules improves intestinal barrier function and intestinal microbiota in patients with mildly active Crohn's disease.
The combination of Mesalamine with live combined Bifidobacterium, Lactobacillus, and Enterococcus capsules demonstrates greater efficacy when compared to Mesalamine alone in the management of mildly active Crohn's disease, as deciphered from a recent research. The study, published in a prestigious medical journal, investigated the impact of combining Mesalamine with live combined Bifidobacterium, Lactobacillus, and Enterococcus capsules on patients with mildly active Crohn's disease.
Overall, 96 patients in the mild activity phase of Crohn's disease were randomly allocated to either the control group, receiving Mesalamine alone, or the observation group, receiving Mesalamine in combination with the probiotic capsules. Following a four-week treatment period, the patients were evaluated for clinical effectiveness, T lymphocyte subsets, intestinal microbiota counts, serum inflammatory factors, and mucosal barrier function indicators.
The results were striking. The observation group, receiving the combined treatment, illustrated a substantially higher total clinical effective rate when compared to the control group, as shown in Table 1:
Furthermore, subjects in the observation group exhibited elevated levels of beneficial bacteria like Lactobacillus acidophilus and Bifidobacterium longum, along with higher serum levels of anti-inflammatory cytokine interleukin-10. Conversely, detrimental bacteria like Bacteroides vulgatus were reduced in the observation group. Additionally, markers of inflammation such as tumor necrosis factor-α, interleukin-6, and C-reactive protein were lower in the observation group, indicating a reduced inflammatory response.
Moreover, the combined treatment led to improvements in T lymphocyte subsets, with higher levels of CD4+ cells, and a favorable CD4+/CD8+ ratio. Importantly, indicators of mucosal barrier function were also enhanced in the observation group. In terms of adverse effects, no inter-group profound difference was noted. The study underscores the potential of probiotic supplementation in modulating the intestinal microbiota and improving clinical outcomes for Crohn's disease patients.
Journal of Investigative Surgery
Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn's Disease Patients
Meiqin Shen et al.
Comments (0)